XYone Therapeutics

Private

#Oncology #Antibody-Drug Conjugates #Endocrinology

Clinical-stage biotechnology company developing first-in-class MUC1-C-targeted immuno-oncology therapeutics along with diagnostics and formulations for endocrine disorders. Its lead antibody-drug conjugate XYA02 has FDA orphan drug designation in gastric cancer and dosed its first patient in September 2026.

Company Info

Sector:Biotechnology

Headquarters:Canton, Massachusetts, USA

Founded:2021

Website:xyonetx.com/

Upcoming Milestones & Key Dates

2026-12

Clinical readout

XYA02 Phase 1 dose-escalation update

2027

Trial milestone

XYA02 expansion cohorts in MUC1-C-positive solid tumors

Clinical Development Pipeline

XYA02 (AT2021)

Target: MUC1-C

Gastric cancer (orphan drug designation)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

XYA02 (AT2021)

Target: MUC1-C

Solid tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Endocrine diagnostic programs

Target: Hormone measurement

Hypogonadism / thyroid disorders

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Shalender Bhasin

Co-founder

Ravi Jasuja

Co-founder

Anshu Goyal

Co-founder

Careers & Job Openings

See all open roles

Careers

See posting

Apply Now →